stockrow
Saturday 7 November 2026
Export KLRA’s income statement to Excel — free account
Kailera Therapeutics, Inc.
KLRA Healthcare Biotechnology
- EPS
- +100.0%
- Free cash flow
- −326.0%
Quarter to September 2026, against a year earlier
12.97
0.80
+6.57%
Follow KLRA
Alert me
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
25.70 | 12.01 |
Net Debt/EBITDA |
0.00 | 3.46 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.00 | 0.81 |
Capex/Depreciation |
0.00 | (6.74) |
| — | 51.79% | |
| — | (34.21%) | |
ROIC |
0.00% | (110.14%) |
Return on Tangible Assets |
0.00% | (29.03%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% |
Free Cash Flow per Share |
0.00 | (778.97) |
Cash per Share |
0.00 | 3,478.06 |
Shareholders Equity per Share |
0.00 | 4,050.36 |
Interest Debt per Share |
— | 0.00 |
Book value per Share |
0.00 | 4,050.36 |
Free Cash Flow |
0.00 | (122.30) |
Working Capital |
170.70 | 511.13 |
Capital Expenditures |
0.00 | (2.09) |
Net Current Asset Value |
170.70 | 501.15 |
| Other line items | ||
Quick Ratio |
25.35 | 11.77 |
Depreciation/Fixed assets |
0.00 | 0.16 |
Cash ROIC |
0.00% | (10.35%) |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
— | 0.00 |
Operating CF per Share |
0.00 | (765.67) |
Capex per Share |
0.00 | (13.30) |
Average Payables |
— | 4.77 |
Average Assets |
— | 435.37 |
Average Common Equity |
— | (287.61) |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026